Search Main navigation Intro to CF Managing CF Research & Clinical Trials Support Community Blog News GET INVOLVED DONATE CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure. Jun. 15, 2021 | 4 min read BETHESDA, Md. -- Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome challenges to developing genetic therapies for cystic fibrosis. The collaboration is part of the Foundation's $500 million Path to a Cure to accelerate treatments for the underlying cause of disease and a cure for every person with CF. In recent years there has been significant growth in scientific understanding and investment in genetic therapies; however, translating that progress into CF can be more challenging than other disease areas due to the body's natural defense mechanisms, including physical barriers in the lungs. The collaboration will leverage Deep Science Ventures' ideation-based innovation and venture creation to identify promising early technologies. Deep Science Ventures and the CF Foundation will work together to assess pressing barriers to genetic therapies in CF, explore the feasibility of potential solutions, and design proof-of-concept studies. The work will be led by a founding analyst based at Deep Science Ventures and overseen by a joint steering committee composed of leaders from both organizations. “Our goal is therapies and a cure for 100% of people with CF. By aligning the Foundation's CF expertise and scientific capabilities with Deep Science Ventures' track record of uncovering innovative technologies, this agreement has the potential to push the CF field forward and significantly accelerate progress toward future therapies for CF,” said Kara Foshay, PhD, director of biopharma and medicine programs at the Cystic Fibrosis Foundation. "Deep Science Ventures has a novel approach to innovation and company creation. Using a proprietary methodology, and placing collaboration at the forefront, we identify tailored solutions to major societal problems. We are excited to apply our expertise together with the CF Foundation to significantly accelerate progress towards future therapies for cystic fibrosis,” said Kerstin Papenfuss, PhD, associate director of pharmaceuticals at Deep Science Ventures. About the Path to a Cure The CF Foundation launched its $500 million Path to a Cure initiative in October 2019. This initiative centers around three core strategies to address the underlying cause of CF: repairing broken CFTR protein, restoring CFTR protein when none exists, and fixing or replacing the underlying genetic mutation to address the root cause of CF. Each approach requires a different set of scientific tools and knowledge, leading the Foundation to bring together researchers and industry leaders from a range of disciplines to advance multiple areas of research in parallel. Learn more about the Path to a Cure and related funding opportunities on cff.org. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org. Media Contact Ashley Mahoney Email: amahoney@cff.org Phone: 240-200-3754 Industry Contact Lindsey Beaman Email: lbeaman@cff.org Phone: 240-200-3780 Share this article Topics ABOUT THE CF FOUNDATION | OUR RESEARCH APPROACH Recent news Cystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering Medicines, a Flagship Pioneering Initiative News | 4 min read CF Foundation Strongly Urges Universal Masking in Schools News | 2 min read CF Foundation Launches Lung Transplant Biorepository and Patient Registry News | 4 min read You might also be interested in... RESEARCH | ABOUT THE CF FOUNDATION | OUR RESEARCH APPROACH Cystic Fibrosis Foundation Announces Nine Research Agreements to Advance Its Path to a Cure 4 min read RESEARCH | ABOUT THE CF FOUNDATION | OUR RESEARCH APPROACH CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy 4 min read RESEARCH | ABOUT THE CF FOUNDATION | OUR RESEARCH APPROACH CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative 5 min read Stay up to date with The Foundation Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox. SUBSCRIBE Footer LIFE WITH CF Intro to CF Managing CF Research & Clinical Trials CF COMMUNITY Get Involved Local Chapter Community Blog FOR PROFESSIONALS Researchers Medical Professionals Press ABOUT US About Us News Donate HELP Find a Care Center Get Help Contact Us Sign up for The Foundation's newsletter SIGN UP Facebook Twitter Youtube Instagram Contact Footer legal Privacy Email Opt Out Terms of Use Disclosures Jump back to top